Giotalk_Module 1: Advancements in the treatment of NSCLC

eLearning on BoehringerOne

Visit BoehringerOne.com

Giotalk Foundation	Duration
Session 1 RWE and how ultilize RWE into practices?	14:00
Session 2 EGFR TKIs are not Equal: What RCTs tell us	05:00
Session 3 EGFR TKIs, are they all the same in the real world?	05:00
Session 4 Choice of EGFR TKI in Patients with Brain Metastases (RCT)	02:00
Session 5 Role of EGFR TKIs in uncommon and compound mutations	09:00
Session 6 First-line EGFR TKI choice to optimize treatment sequence	05:00
Session 7 Maximizing EGFR TKI treatment in NSCLC	09:00
Session 8 Treating NSCLC with T790M mutations	06:00
Session 9 Choice of EGFR TKI in Patients with Brain Metastases (RWE)	02:00
Session 10 Tolerability-Guided Dose Modification of Afatinib: Results from RealGiDo RWE	20:00
Session 11 Real-world study demonstrated benefits for Asian EGFR M+ NSCLC patients with sequential Afatinib-Osimertinib	19:00
Session 12 Clonal Evolution in EGFR M+ NSCLC: Implications in Therapeutic Sequencing	04:00

Course details